Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Accured Expenses (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Change in Accured Expenses for 6 consecutive years, with $27000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 105.05% year-over-year to $27000.0, compared with a TTM value of -$4.7 million through Sep 2025, down 448.44%, and an annual FY2024 reading of -$537000.0, down 126.57% over the prior year.
  • Change in Accured Expenses was $27000.0 for Q3 2025 at Ovid Therapeutics, up from -$3.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.1 million in Q2 2024 and bottomed at -$3.4 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is -$482316.6, with a median of -$1000.0 recorded in 2025.
  • Peak annual rise in Change in Accured Expenses hit 201.78% in 2024, while the deepest fall reached 622.77% in 2024.
  • Year by year, Change in Accured Expenses stood at $748263.0 in 2021, then tumbled by 259.64% to -$1.2 million in 2022, then soared by 125.36% to $303000.0 in 2023, then plummeted by 622.77% to -$1.6 million in 2024, then surged by 101.7% to $27000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for OVID at $27000.0 in Q3 2025, -$3.1 million in Q2 2025, and -$1000.0 in Q1 2025.